Single vs. Multiple fraction non-Inferiority trial of Stereotactic Ablative Radiotherapy for the Comprehensive treatment of Oligo-metastases/progression.
About this trial
The SIMPLIFY SABR COMET (CTRIAL-IE 24-09) is currently open at:
- Cork University Hospital
- University Hospital Galway
- UPMC Hillman Cancer Centre, Waterford
- The Beacon Hospital
- Bon Secours UPMC Cork
- St. Luke’s Radiation Oncology Network (SLRON)
What is the goal of this study?
The goal of the study is to determine what the side effects of single or multiple fraction Stereotactic Ablative Radiotherapy (SABR) are, and what is the most optimal treatment which could be used in future studies.
What happens to patients as part of this trial?
- SABR is a modern form of radiotherapy that delivers very high-dose treatment in just less hospital visits than standard radiotherapy.
- If a patient joins this study they will randomly be assigned to receive treatment in a single visit versus in 3-5 treatment visits.
- Patients will then be followed up by their radiation oncologist and the clinical trials team for 5 years to assess any side-effects of treatment.
- The study is investigating whether single treatment SABR has side effects that are similar to multiple treatment visit SABR.
Who can take part?
You may be eligible if:
- You are 18 or older,
- You have one to five oligometastatic or oligo-progressive lesions (this means lesions which have spread from another part of the body).
- You meet other medical criteria checked by your team.
Study Oversight
Professor Aisling Barry is the Chief Investigator of the study in Ireland.
The study is sponsored nationally by Cancer Trials Ireland.
BC Cancer in Canada are the international study sponsors and Professor Robert Olsen is the Sponsor-Investigator.